Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options

Journal of Alzheimer's Disease

Volumn 67, Issue 3, 2019, Pages 779-794

  Cummings, Jeffrey L ^a   Tong, Gary ^b   Ballard, Clive ^c  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b LUNDBECK RESEARCH USA   (United States)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

Alzheimer's disease; cholinesterase inhibitor; dementia; disease modifying; memantine; symptomatic; treatment combination

Indexed keywords

ATABECESTAT; ENALAPRIL MALEATE; MEMANTINE; RASAGILINE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; COMBINATION DRUG THERAPY; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; DRUG THERAPY, COMBINATION; HUMANS; NOOTROPIC AGENTS;

EID: 85061755242     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-180766     Document Type: Review

References (86)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
2. Alzheimer's Association (2016) 2016 Alzheimer's disease facts and figures. Alzheimers Dement 12, 459-509.
3. Alzheimer's Disease International,World Alzheimer Report 2016: The global impact of dementia, Alzheimer's Disease International, https://www.alz.co.uk/research/World AlzheimerReport2016.pdf, Accessed on March 17, 2017.
4. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7, 137-152.
5. Ringman JM, Goate A, Masters CL, Cairns NJ, Danek A, Graff-Radford N, Ghetti B, Morris JC, Dominantly Inherited Alzheimer Network (2014) Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. Curr Neurol Neurosci Rep 14, 499.
6. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8, 595-608.
7. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739, 198-210.
8. Mufson EJ, Counts SE, Perez SE, Ginsberg SD (2008) Cholinergic system during the progression of Alzheimer's disease: Therapeutic implications. Expert Rev Neurother 8, 1703-1718.
9. Yan R, Vassar R (2014) Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 13, 319-329.
10. Cummings JL, MorstorfT, ZhongK(2014) Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res Ther 6, 37.
11. Aricept (2015) (donepezil hydrochloride). Full Prescribing Information, Eisai Inc., Woodcliff Lake, NJ.
12. Exelon (2015) (rivastigmine tartrate). Full Prescribing Information, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
13. Exelon Patch (2016) (rivastigmine transdermal system). Full Prescribing Information, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
14. Razadyne (2016) (galantamine hydrobromide). Full Prescribing Information, Janssen Pharmaceuticals Inc., Titusville, NJ.
15. Namenda XR (2014) (memantine hydrochloride). Full Prescribing Information, Forest Pharmaceuticals Inc., St. Louis, MO.
16. Namzaric (2016) (memantine and donepezil hydrochlorides). Full Prescribing Information, Allergan USA, Inc., Irvine, CA.
17. Mizuno S, Iijima R, Ogishima S, Kikuchi M, Matsuoka Y, Ghosh S, Miyamoto T, Miyashita A, Kuwano R, Tanaka H (2012) AlzPathway: A comprehensive map of signaling pathways of Alzheimer's disease. BMC Syst Biol 6, 52.
18. Schmitt B, Bernhardt T, Moeller HJ, Heuser I, Frolich L (2004) Combination therapy in Alzheimer's disease: A review of current evidence. CNS Drugs 18, 827-844.
19. Fessel WJ (2017) Concordance of several subcellular interactions initiates Alzheimer's dementia: Their reversal requires combination treatment. Am J Alzheimers Dis Other Demen 32, 166-181.
20. Tomaszewski S, Gauthier S, Wimo A, Rosa-Neto P (2016) Combination therapy of anti-Tau and anti-Amyloid drugs for disease modification in early-stage Alzheimer's disease: Socio-economic considerations modeled on treatments for tuberculosis, HIV/AIDS and breast cancer. J Prev Alzheimers Dis 3, 164-172.
21. Toews ML, Bylund DB (2005) Pharmacologic principles for combination therapy. Proc Am Thorac Soc 2, 282-289.
22. Barbeau A, Mars H, Botez MI, Joubert M (1972) Levodopa combined with peripheral decarboxylase inhibition in Parkinson?s disease. Can Med Assoc J 106, 1169-1174.
23. Pioro EP, Brooks BR, Cummings. J Schiffer R Thisted RA Wynn D Hepner A Kaye R Safety, Tolerability and Efficacy Results Trial of AVP-923 in PBA Investigators (2010) Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 68, 693-702.
24. Cummings. J, Fox N (2017) Defining disease modifying therapy for Alzheimer's disease. J Prev Alzheimers Dis 4, 109-115.
25. Wang A, Das P, Switzer RC, 3rd, Golde TE, Jankowsky JL (2011) Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci 31, 4124-4136.
26. Jack CR, Jr., Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS, Alzheimer's Disease Neuroimaging, Initiative (2011) Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 68, 1526-1535.
27. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61, 561-566.
28. Youdim MB, Weinstock M (2001) Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol 21, 555-573.
29. Merck, Press Release Merck announces discontinuation of APECS study evaluating verubecestat (MK-8931) for the treatment of people with prodromal Alzheimer's disease, http://www.mrknewsroom.com/news-release/research-And-development-news/merck-Announces-discontinuation-Ape cs-study-evaluating-ve, Accessed on June 7, 2018.
30. Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, DockendorfMF, EganM, Ereshefsky L, Hodgson RA, Hyde LA, Jhee S, Kleijn HJ, Kuvelkar R, LiW, Mattson BA,Mei H, Palcza. J, Scott JD,Tanen M,TroyerMD,Tseng JL, Stone JA, Parker EM, Forman MS (2016) The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-Amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med 8, 363ra450.
31. EganMF,Kost. J,Tariot PN, Aisen PS, Cummings JL,Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D (2018) Randomized trial of verubecestat for mild-To-moderate Alzheimer's disease. N Engl J Med 378, 1691-1703.
32. Merck, Press Release: Merck announces EPOCH study of verubecestat for the treatment of people with mild to moderate Alzheimer's disease to stop for lack of efficacy, https://www.businesswire.com/news/home/201702140062 78/en/Merck-Announces-EPOCH-Study-Verubecestat-Tre atment-People, Accessed on June 7, 2018.
33. Schenk D, Basi GS, Pangalos MN (2012) Treatment strategies targeting amyloid beta-protein. Cold Spring Harb Perspect Med 2, a006387.
34. Sevigny. J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O?Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 537, 50-56.
35. Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, Errico F, Mercuri NB, Nicoletti F, Nistico R (2013) Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Drug Des Devel Ther 7, 1359-1364.
36. Mackey H, Cho W, Ward M, Fang Y, Suliman S, Ho C, Paul R (2016) Exploratory analyses of cognitive effects of crenezumab in a mild Alzheimer's disease subpopulation of a randomized, double-blind, placebo controlled, parallelgroup phase 2 study (ABBY). Alzheimers Dement 12, P610.
37. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Bapineuzumab Clinical Trial Investigators (2014) Two phase 3 trials of bapineuzumab in mild-To-moderate Alzheimer's disease. N Engl J Med 370, 322-333.
38. H. Lundbeck, A/S Press release: Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer's disease, http://investor.lundbeck.com/releasedetail.cfm?releaseid=990541, Accessed on June 12, 2018.
39. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, Alzheimer's Disease Cooperative Study Steering Committee, Solanezumab Study, Group (2014) Phase 3 trials of solanezumab for mild-To-moderate Alzheimer's disease. N Engl J Med 370, 311-321.
40. Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C, Dian-Tu Pharma Consortium for the Dominantly Inherited Alzheimer Network (2017) The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement 13, 8-19.
41. Janssen Press Release: Update on Janssen?s BACE Inhibitor Program Regarding the Dominantly Inherited Alzheimer's Network Trial (DIAN-TU). Janssen, Titusville, NJ. Available at: https://www.janssen.com/update-janssens-bace-inh ibitor-program-regarding-DIAN-TU-july-2018. Accessed December 04, 2018.
42. Wischik CM, Harrington CR, Storey JM (2014) Tauaggregation inhibitor therapy for Alzheimer's disease. Biochem Pharmacol 88, 529-539.
43. Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G (2016) Tau-centric targets and drugs in clinical development for the treatment of Alzheimer's disease. Biomed Res Int 2016, 3245935.
44. Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR,Wischik CM (2016) Efficacy and safety of tau-Aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: A randomised, controlled, double-blind, parallel-Arm, phase 3 trial. Lancet 388, 2873-2884.
45. Piette F, Belmin J,Vincent H, Schmidt N, Pariel S,VernyM, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, Dubreuil P, Moussy A, Hermine O (2011) Masitinib as an adjunct therapy for mild-To-moderate Alzheimer's disease: A randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 3, 16.
46. Shaik-Dasthagirisaheb YB, Conti P (2016) The role of mast cells in Alzheimer's disease. Adv Clin Exp Med 25, 781-787.
47. Hori Y, Takeda S, Cho H, Wegmann S, Shoup TM, Takahashi K, Irimia D, Elmaleh DR, Hyman BT, Hudry E (2015) A Food and Drug Administration-Approved asthma therapeutic agent impacts amyloid beta in the brain in a transgenic model of Alzheimer disease. J Biol Chem 290, 1966-1978.
48. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E (2008) The antioxidant properties of serum albumin. FEBS Lett 582, 1783-1787.
49. Boada M, Ramos-Fernandez E, Guivernau B, Munoz FJ, Costa M, Ortiz AM, Jorquera JI, Nunez L, Torres M, Paez A (2016) Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study. Neurologia 31, 473-481.
50. Deane RJ (2012) Is RAGE still a therapeutic target for Alzheimer's disease? Future Med Chem 4, 915-925.
51. vTv Therapeutics, Press Release: vTv Therapeutics announces topline results from the first STEADFAST phase 3 study evaluating azeliragon in people with mild Alzheimer's disease, http://ir.vtvtherapeutics.com/phoenix. zhtml?c=254081&p=irol-newsArticle print&ID=2341681, Accessed on June 12, 2018.
52. Marvanova M (2014) Antipsychotic use in elderly patients with dementia: Efficacy and safety concerns. Mental Health Clin 4, 170-176.
53. Henry G, Williamson D, Tampi RR (2011) Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen 26, 169-183.
54. Ballard C, Waite J. (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev, CD003476.
55. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA, CATIE-AD Study Group (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355, 1525-1538.
56. Layton D, Harris S, Wilton LV, Shakir SA (2005) Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol 19, 473-482.
57. Risperidal (2009) (risperidone). Full Prescribing Information, Ortho-McNeil-Janssen Pharmaceuticals Inc, Titusville, NJ.
58. ZYPREXA (2018) (olanzapine). Full Prescribing Information, Eli Lilly and Company, Indianapolis, IN.
59. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, Gurwitz JH, Rochon PA (2007) Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146, 775-786.
60. Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU (2016) Second generation antipsychotics in the treatment of major depressive disorder: An update. Chonnam Med J 52, 159-172.
61. Otsuka and Lundbeck, Press Release: Otsuka and Lundbeck announce improvement of agitation symptoms related to Alzheimer's-Type dementia following treatment with brexpiprazole relative to placebo, http://investor.lundbeck.com/releasedetail.cfm?releaseid=1023859, Accessed on June 5, 2018.
62. Lundbeck and Otsuka, Press Release: Lundbeck and Otsuka will initiate a third phase III trial to evaluate the use of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, http://investor.lundbeck. com/releasedetail.cfm?ReleaseID=1046327, Accessed on June 7, 2018.
63. Cummings JL (2008) Effect of cholinesterase inhibitors on behavior. Neurobiol Aging 29, S6.
64. Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, Ballard C, Boustani M, Katona C, Livingston G (2012) Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double-blind placebo controlled trial. PLoS One 7, e35185.
65. Upton N, Chuang TT, Hunter AJ, Virley DJ (2008) 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 5, 458-469.
66. Wilkinson D, Windfeld K, Colding-Jorgensen E (2014) Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): A randomised, double-blind, placebocontrolled phase 2 trial. Lancet Neurol 13, 1092-1099.
67. Atri A, Frolich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL (2018) Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: Three randomized clinical trials. JAMA 319, 130-142.
68. Maher-Edwards G,Watson C, Ascher J, Barnett C, Boswell D, Davies J, Fernandez M, Kurz A, Zanetti O, Safirstein B, Schronen JP, Zvartau-Hind M, Gold M (2015) Two randomized controlled trials of SB742457 in mild-Tomoderate Alzheimer's disease. Alzheimers Dement (N Y) 1, 23-36.
69. Axovant, Press Release: Axovant announces negative topline results of intepirdine phase 3 mindset trial in Alzheimer's disease, http://investors.axovant.com/news-rel eases/news-release-details/axovant-Announces-negative-To pline-results-intepirdine-phase-3, Accessed on June 5, 2018.
70. Axovant, Press Release: Axovant announces negative results for intepirdine in phase 2b headway and pilot phase 2 gait and balance studies, http://investors.axovant.com/news-releases/news-release-details/axovant-Announces-ne gative-results-intepirdine-phase-2b-headway, Accessed on February 20, 2018.
71. Youdim MB, Gross A, Finberg JP (2001) Rasagiline [N-propargyl-1R(+)-Aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132, 500-506.
72. Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T (2005) Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79, 172-179.
73. Cortice Biosciences, Press Release: Cortice Biosciences announces presentation of results from placebo-controlled phase 1 clinical trials evaluating TPI 287 for treatment of Alzheimer's disease and related tauopathies, https://globe newswire.com/news-release/2017/11/03/1174533/0/en/Co rtice-Biosciences-Announces-Presentation-of-Results-from-Placebo-Controlled-Phase-1-Clinical-Trials-Evaluating-T PI-287-for-Treatment-of-Alzheimer-s-Disease-And-Related-Tauopathie.html, Accessed on April 30, 2018.
74. Hendrix JA, Bateman RJ, Brashear HR, Duggan C, Carrillo MC, Bain LJ, DeMattos R, Katz RG, Ostrowitzki S, Siemers E, Sperling R, Vitolo OV (2016) Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. Alzheimers Dement 12, 623-630.
75. Evans SR (2010) Clinical trial structures. J Exp Stroke Transl Med 3, 8-18.
76. Messmer MF, Wilhelm EE, Shoulson I (2017) I-SPY 2 breast cancer trial as a model for innovation in Alzheimer disease therapies. JAMA Neurol 74, 1027-1028.
77. European Prevention of Alzheimer's Dementia Consortium: Project objectives, http://ep-Ad.org/project-objectives/, Accessed on February 16, 2018.
78. ClinicalTrials.gov, Dominantly Inherited Alzheimer Network Trial: An opportunity to prevent dementia. A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer's disease caused by a genetic mutation (DIAN-TU), https://www. clinicaltrials.gov/ct2/show/study/NCT01760005, Accessed on February 16, 2018.
79. University of Edinburgh, European prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS) (EPAD LCS), https://clinicaltrials.gov/ct2/show/NC T02804789, Accessed on April 23, 2018.
80. Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S, European Prevention of Alzheimer's Dementia Consortium (2016) Development of interventions for the secondary prevention of Alzheimer's dementia: The European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry 3, 179-186.
81. European Medicines Agency, Guideline on clinical development of fixed combination medicinal products, http://www. ema.europa.eu/docs/en GB/document library/Scientific gu ideline/2017/03/WC500224836.pdf, Accessed on June 7, 2018.
82. US Food and Drug Administration, Guidance for Industry: codevelopment of two or more unmarketed investigational drugs for use in combination, https://www.fda.gov/downloads/drugs/guidances/ucm236669.pdf, Accessed on June 7, 2018.
83. Hunter NL, Sherman RE (2017) Combination products: Modernizing the regulatory paradigm. Nat Rev Drug Discov 16, 513-514.
84. US Food and Drug Administration, Guidance for Industry: S9 nonclinical evaluation for anticancer pharmaceuticals, https://www.fda.gov/downloads/Drugs/Guidances/ucm085 389.pdf, Accessed on June 7, 2018.
85. US Food and Drug Administration, Human immunodeficiency virus-1 infection: Developing antiretroviral drugs for treatment. Guidance for Industry, https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformatio n/guidances/ucm355128.pdf, Accessed on January 29, 2018.
86. US Food and Drug Administration, Guidance for Industry: Pulmonary tuberculosis: Developing drugs for treatment, https://www.fda.gov/downloads/Drugs/GuidanceComplian ceRegulatoryInformation/Guidances/UCM373580.pdf, Accessed on June 7, 2018.